Fresenius Medical Care AG with ticker code (FMS) now have 3 total analysts covering the stock. The consensus rating is “Hold”. The range between the high target price and the low target price is between 45.74 and 30.13, with the middle target price at 36.89. Given that the stock’s previous close was at 33.39, this indicates that there is 10.5% upside potential. The 50-day moving average now sits at 32.79 and the 200-day moving average is at 36.46. The market cap of the company is $19,866 million. Visit the company’s website at: https://www.freseniusmedicalcare.com
The potential market cap would be $21,948 million based on market consensus.
You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure. The company also develops, manufactures and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granules, bloodlines, kidney pharmaceuticals and water treatment systems; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires and licenses renal pharmaceuticals; provides kidney medications and supplies to patients at home or in dialysis clinics; and provides vascular, cardiovascular and endovascular specialty services, an outpatient vascular surgery center, and nephrology and cardiology medical services. The company sells its products directly to dialysis clinics, hospitals and specialty treatment clinics, as well as through local sales forces, independent distributors, resellers and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.